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Abstract 
Autism spectrum disorder is a prevalent neurodevelopmental disorder with no established 
pharmacological treatment for its core symptoms. Although previous literature has shown that 
single-dose administration of oxytocin temporally mitigates autistic social behaviours in 
experimental settings, it remains in dispute whether such potentially beneficial responses in 
laboratories can result in clinically positive effects in daily-life situations, which are 
measurable only in long-term observations of individuals with the developmental disorder 
undergoing continual oxytocin administration. Here, to address this issue, we performed an 
exploratory, randomised, double-blind, placebo-controlled, crossover trial employing 20 high-
functional adult males with autism spectrum disorder. Data obtained from 18 participants who 
completed the trial showed that six-week intranasal administration of oxytocin significantly 
reduced autism core symptoms specific to social reciprocity, which was clinically evaluated by 
Autism Diagnostic Observation Scale (P = 0.034, PFDR < 0.05, Cohen’s d = 0.78). Critically, 
the improvement of this clinical score was accompanied by oxytocin-induced enhancement of 
task-independent resting-state functional connectivity between anterior cingulate cortex and 
dorso-medial prefrontal cortex (rho = –0.60, P = 0.011), which was measured by functional 
MRI. Moreover, using the same social-judgment task as one used in our previous single-dose 
oxytocin trial, we confirmed that the current continual administration also significantly 
mitigated behavioural and neural responses during the task, both of which were originally 
impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P 
= 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal 
activity: P = 0.0014, d = 0.92; all, PFDR < 0.05). Furthermore, despite its longer administration, 
these effect sizes of the six-week intervention were not larger than those seen in our previous 
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single-dose intervention. These findings not only provide the evidence for clinically beneficial 
effects of continual oxytocin administration on the core social symptoms of autism spectrum 
disorder with suggesting its underlying biological mechanisms, but also highlight the necessity 
to seek optimal regimens of continual oxytocin treatment in future studies. 
 
Keywords 
Clinical trial, functional MRI, Neuropeptide, Pervasive developmental disorder, resting-state 
functional connectivity 
 
Abbreviations 
ASD, autism spectrum disorder; fMRI, functional MRI; ACC, anterior cingulate cortex; 
dmPFC, dorso-medial prefrontal cortex; rsFC, resting-state functional connectivity; PPI, 
psycho-physiological interaction.   
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Introduction 
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with over 1% of 
prevalence, and has been given no established pharmacological treatment for its core symptoms 
(Centres for Disease Control and Prevention, 2012). Single-dose oxytocin is currently 
considered to mitigate its deficits in social cognitions in experimental settings (Andari et al., 
2010; Aoki, Watanabe, et al., 2014; Aoki, Yahata, et al., 2014; Bakermans-Kranenburg and 
van I Jzendoorn, 2013; Domes et al., 2014; Gordon et al., 2013; Hollander et al., 2007; Lin et 
al., 2014; Veening and Olivier, 2013; Watanabe, Abe, et al., 2014; Yamasue et al., 2012; Zink 
and Meyer-Lindenberg, 2012); however, there is no clear evidence that such potentially 
beneficial responses in laboratories can consequently induce significant effects in ASD 
individuals in clinical and daily-life settings after continual intervention, which is impeding 
practical applications of this neuropeptide.  
Although a recent single-armed, open-label trial employing eight ASD males has 
reported the safety of continual oxytocin administration, and suggested its potentially positive 
influence on the communication and social-interaction scores of Autism Diagnostic 
Observation Schedule-Generic and on the caregivers’ reports about reciprocal communication 
quality (Tachibana et al., 2013), previous randomised trials of continual administration have 
not detected clinically valuable effects of oxytocin on ASD with statistical significance. A six-
week trial, which compared oxytocin-treated ten ASD adults with placebo-given nine ASD 
adults, reported behavioural improvement only in an experimentally-measured ability to detect 
emotion, but could not find significant benefits on clinically-measured social deficit scores 
(Anagnostou et al., 2014). Other recent trials, in which oxytocin/placebo were administered to 
19/19 ASD children over five days (Dadds et al., 2014) or 26/24 children over eight weeks 
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(Guastella et al., 2014), could not detect any significant changes in any social behaviours of 
the children, either.  
Here, we assumed that this discrepancy between single-dose and continual 
administration of oxytocin indicates (i) the necessity to use ASD-specific clinical scoring 
systems for detecting responses to the continual intervention, and (ii) the possibility that 
continual oxytocin treatment does not amplify effects of single-dose administration. In fact, the 
hypothesis (ii) was also suggested by a recent study that, using prairie voles, implied that 
chronic oxytocin treatment could trigger down-regulation of endogenous oxytocin or its 
receptor, and reduce acute beneficial effects of the neuropeptide (Bales et al., 2013). 
We tested these two hypotheses in the current exploratory randomised, double-blind, 
placebo-controlled, crossover trial. To examine the hypothesis (i), we assessed clinical effects 
of six-week administration of oxytocin using Autism Diagnostic Observation Scale (ADOS) 
(Lord et al., 1989), which is originally a standard diagnosis tool for ASD but recently has been 
increasingly adopted as a primary outcome in ASD-related trials (Aldred et al., 2004; Green et 
al., 2010; Howlin et al., 2007; Owley et al., 2001; Wong and Kwan, 2010). In addition, we 
explored potential biological mechanisms underlying these clinical effects by examining 
intrinsic functional connectivity in the medial prefrontal cortex (mPFC), which are known to 
be significantly altered in ASD (Cherkassky et al., 2009; Cox et al., 2012; Di Martino et al., 
2014; Itahashi et al., 2014; Jung et al., 2014; Lynch et al., 2013).   
To evaluate the hypothesis (ii), we used the same psychological task as one in our 
previous single-dose trial (Watanabe, Abe, et al., 2014), and directly compared magnitudes of 
oxytocin’s behavioural and neural effects between six-week and single-dose interventions. For 
the precise comparison, we performed this task-based evaluation in the virtually same time 
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schedule as in our previous single-dose trial, and measured the behavioural and neural 
responses on the last day of each six-week administration of oxytocin/placebo.  
 
 
Methods 
Study design and participants 
This randomised, double-blind, placebo-controlled, crossover trial was primarily conducted in 
an outpatient clinic of The University of Tokyo Hospital. The recruitment process, data and 
drug management, informed-consent collection, confirmation of diagnosis, six-week interval 
assessment, and two-week interval assessment were performed in this main site. Exceptionally, 
eight participants, who were originally cared for in an outpatient clinic in Showa University 
Karasuyama Hospital, underwent the recruitment process and two-week interval assessments 
in Karasuyama Hospital with the common psychiatrist (HY), who conducted these procedures 
to the other participants at The University of Tokyo Hospital.  
The inclusion criteria comprised ASD diagnosis, gender (male), Full-scale IQ (>80), 
and age (18–55 years old). The exclusion criteria consisted of any history of allergic responses 
to oxytocin, seizures, traumatic brain injury with any known cognitive consequences, loss of 
consciousness for more than 5min, and substance abuse or addiction. Participants with current 
instability of comorbid psychiatric symptoms and contraindications on MRI scanning were also 
excluded. The study protocol is registered in University Hospital Medical Information Network 
Clinical Trials Registry (UMIN000007122). Written informed consent was obtained from all 
the participants. 
As stated in our trial registry, one of the aims of the current explanatory study was to 
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estimate the power of the six-week oxytocin intervention; therefore, from an ethical 
perspective, the number of participants in this trial was set at the presumably minimal number 
for sufficient statistical inference (i.e., N = 20). In fact, 13–16 ASD participants were employed 
in previous studies that reported significant behavioural improvements in psychological tests 
after single-dose oxytocin administration (Andari et al., 2010; Guastella et al., 2010); another 
study employed 15 participants with other psychiatric disorders to show that continual oxytocin 
treatment could induce a significant improvement in clinically evaluated psychiatric symptoms 
(Feifel et al., 2010). Considering these studies, we set the current sample size at 20. 
 
Diagnosis 
A well-experienced psychiatrist (HY) made diagnosis of autistic disorder, Asperger's disorder, 
or pervasive developmental disorder not-otherwise-specified based on the strict criteria of 
Diagnostic and Statistical Manual-Revision IV-Text Revision with more than two months of 
follow-up examinations. Another certified psychiatrist/psychologist confirmed the diagnoses 
using Japanese version of Autism Diagnostic Interview-Revised (Lord et al., 1994) (HK) and 
ADOS (Lord et al., 1989) (MK). All participants exhibited normal or high intelligence in full 
scale of Wechsler Adult Intelligence Scale-Revised, Japanese version (Table 1). 
 
Interventions 
The participants received oxytocin (24 IU, Syntocinon-Spray; Novartis, Switzerland) in the 
morning and afternoon over six consecutive weeks (i.e., 48 IU/day) and placebo in the same 
way with cross-over administration (Fig. 1A).	 The placebo contained all the inactive 
ingredients that were included in the oxytocin spray. All the participants trained intranasal self-
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administration before the trial initiated, and the manner of self-administration was confirmed 
at every two-week assessment point. On the last day of each six-week administration, a half of 
participants underwent clinical assessments, including ADOS, approximately 15min after their 
morning drug inhalation, and MRI-based measurement approximately 40min after their 
afternoon inhalation. The other half underwent these clinical and MRI-based evaluations with 
the order reversed. The examination order was randomly assigned to the participants. This time 
table was anticipated to ensure the same temporal interval between the current oxytocin 
administration and assessments as that in our previous single-dose trial (Watanabe, Abe, et al., 
2014). 
 
Randomization and masking of drug administration 
The manager of randomisation and masking of drug administration randomly assigned the 
participants to the two groups based on computer-generated randomised order: a group to 
which oxytocin was initially administered and one to which placebo was initially given. 
Oxytocin and placebo were stored in spray bottles of the same visual appearance (Victoria 
Pharmacy, Switzerland). The manager completely covered the bottle labels to keep drug types 
unknown to all the participants, their families, experimenters, clinicians and assessors 
including ADOS administrators and assessors.  
 
Outcomes 
The primary outcome was changes in ADOS (module 4, for verbally fluent adults; Lord et al., 
1989) between baseline and the administration endpoints. ADOS was evaluated by four 
administrators (HY/HK/YK/MK), the first three of whom completed a training course for 
research use of ADOS and were validated by the other certified administrator (MK). To 
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minimize inter-administrator variability, all the ADOS scores were rated by a single certified 
administrator (MK) using videos. ADOS scores, such as social reciprocity and communication 
scores, were calculated as the scores in the ADOS diagnostic algorithm. Childhood Autism 
Rating Scale 2 (CARS2) (Schopler et al., 2010) was also rated as a primary outcome by a 
trained assessor (MK) to compare its sensitivity with that of ADOS.  
The secondary outcomes were partly measured as behavioural responses and changes 
in functional MRI (fMRI) signals in a priori defined regions of interest (ROIs) during a social 
psychological task (Fig. 1B). Other secondary outcomes comprised Autism Spectrum Quotient 
(AQ) (Baron-Cohen et al., 2001), Social Responsiveness Scale (SRS) (Constantino et al., 
2003), Repetitive Behaviour Scale (RBS) (Lam and Aman, 2007), State and Trait Anxiety 
Inventory (STAI)-state (Spielberger et al., 1970), Centre for Epidemiologic Studies Depression 
Scale (CESD) (Radloff, 1977), Quality-of-Life questionnaire (QOL) (WHOQOL Group, 
1995), and resting-state functional connectivity (rsFC) between the ROIs (Biswal et al., 1995; 
Fair et al., 2008; Raichle et al., 2001).  
These primary and secondary outcomes were evaluated at the baseline and at six-week 
administration endpoints, whereas some of the other secondary outcomes—including Clinical 
Global Impressions (CGI-EI) (Guy, 1976) and Global Assessment of Functioning (GAF) (Aas, 
2011), and observational items for safety, such as blood pressures and pulse rate—were 
evaluated at every two-week assessment points by a psychiatrist (HY).  
 
MRI data acquisition 
MRI data were acquired in a 3T MRI scanner (GE Healthcare,	UK) in The University of Tokyo 
Hospital with essentially the same protocol as in our previous trial (Watanabe, Abe, et al., 
Page 10 of 37	
2014). The quality of MRI data was controlled by daily monitoring over the course of this trial. 
Trained neuro-radiologists (HT/NY) found no gross anatomical abnormalities in the head of 
any participant.  
For the anatomical co-registration, axial T2-weighted images were recorded (TE = 
82.32ms, TR = 4400ms, FOV = 240×240mm2, matrix = 256×256, slice thickness = 2.5mm, 62 
axial slices). For task-related functional imaging, gradient-echo echo-planar sequences were 
recorded (TR = 3s, TE = 35ms, FA = 80°, 4×4×4mm3, 42 slices, ventral-to-dorsal interleaved 
acquisition). For resting-state functional imaging, different gradient-echo echo-planar 
sequences were adopted (TR = 3s, TE = 30ms, FA = 80°, 3×3×3mm3, 53 slices). The first five 
functional images in each session were discarded to allow for equilibrium of longitudinal 
magnetization. 
 
Regions of interest 
To compare the effect sizes of continual treatment with those of single-dose administration, we 
focused on oxytocin’s effects on brain activity of two pre-defined ROIs (the anterior cingulate 
cortex, ACC; dorsal mPFC, dmPFC; Fig. 1B), because the ROIs were the only regions that 
showed significantly large responses to single-dose oxytocin compared with those to placebo 
in our previous trial (Watanabe, Abe, et al., 2014). Based on this previous study, ACC and 
dmPFC were defined as spheres with a radius of 4mm and a centre at [2, 34, 8] and [0, 30, 52], 
respectively.  
 
Analysis of resting-state fMRI data 
Using resting-state fMRI data, we estimated rsFC between ACC and dmPFC. The fMRI data 
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were recorded while the participants were instructed to vaguely see a fixation point in the centre 
of the screen. We obtained 10min of the resting-state data (5min × 2 sessions) for each 
participant. These fMRI data underwent realignment, slice-timing correction, normalisation to 
the standard template image (ICBM 152), temporal band-pass filtering (0.01–0.1Hz), and 
spatial smoothing (full-width half maximum, FWHM, = 8mm). Corrections for head motion 
(x/y/z/pitch/row/yaw directions), whole-brain signals, ventricular signals, white matter signals, 
and the run effect were preformed based on GLM using corresponding regressors. We finally 
computed the rsFC between the two ROIs by calculating a Pearson’s correlation coefficient 
between the time series of the preprocessed fMRI signals from ACC and dmPFC. 
 
Social cognition task 
For direct comparison, we used the same psychological task and analysis procedures as in our 
previous studies (Watanabe et al., 2012; Watanabe, Abe, et al., 2014). In the fMRI scanner, the 
participants were sequentially presented with 80 monochrome short movies (1.5s) in which 
one of 20 professional actors spoke different emotional words (verbal information, V) with 
emotional facial and vocal expressions (nonverbal information, NV); for each movie, the 
participants were asked to make a judgement whether the actor looked like a friend or foe to 
them (Fig. 1B). The stimuli consisted of two types of congruent stimulus and two types of 
incongruent stimulus: the congruent stimuli comprised ‘positive NV and V’ (NV+V+) or 
‘negative NV and V’ (NV–V–); the incongruent stimuli comprised ‘positive NV and negative 
V’ (NV+V–) or ‘negative NV and positive V’ (NV–V+). After sufficient training with different 
stimuli, the participants were pseudo-randomly presented with these movies and made 
friend/foe judgements. This psychological task took approximately 12min (6min × 2 sessions).  
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Analysis of behavioural responses during a psychological task 
If a participant made a friend/foe judgment mainly based on nonverbal information, the 
response was classified to a nonverbal-information-based judgment (NVJ). Otherwise, the 
response that was mainly based on verbal information was labelled as a verbal-information-
based judgement (VJ). For instance, the ‘friend’ judgment of a stimulus with positive facial 
and vocal expressions and a negative word was classified to NVJ, because the participant was 
supposed to emphasise positive nonverbal information rather than negative verbal information. 
Note that VJ trials were also defined as a part of responses to incongruent stimuli. As in our 
previous studies (Watanabe et al., 2012; Watanabe, Abe, et al., 2014; Watanabe, Yahata, et al., 
2014), we focused on behavioural and neural responses during NVJ (Fig. 3A). We counted the 
number of NVJs for each participant for each assessment day, and also calculated the response 
time for NVJ, which was defined as a time between the start of the movie stimuli and pressing 
a button for indicating their judgments.  
Eye gaze was tracked during the task using remote infrared-light camera. The data were 
analysed in the same manner as in our previous trial as follows (Watanabe, Abe, et al., 2014): 
we first smoothed the data with a Gaussian filter, and detected blinking and artefacts; we then 
calculated the average fixation durations on the eyes or nose/mouth areas relative to the whole 
screen. The fixations were defined as maintaining a gaze on a target area for at least 100ms. 
The eye or nose/mouth areas were determined as a common area for all the movies in a 
relatively liberal manner.  
Using the data about these behavioural responses, we calculated the effects of oxytocin 
and placebo. Each behavioural effect of a given drug was defined as a change between the start 
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and end of the drug administration (i.e., effect = end value – start value). 
 
Analysis of brain activity during task 
In SPM8 (www.fil.ion.ucl.ac.uk/spm/), the task-related fMRI data underwent realignment, 
correction of slice timing, normalisation to the default template with interpolation to a 2-mm 
cubic space, spatial smoothing (FWHM = 8mm, Gaussian filter), and high-pass temporal 
filtering (128s). At a single-participant level, we used a GLM for an event-related fMRI design 
with eight regressors (the four types of stimulus × the two types of response), and calculated 
the difference in fMRI signals for each ROI between NVJ and VJ, which was defined as NVJ-
specific activity (i.e., NVJ–VJ). We then evaluated effects of oxytocin and placebo, which were 
defined as differences in brain activity between the start and end of the drug administrations. 
Task-related functional connectivity between ACC and dmPFC was estimated by 
calculating the psycho-physiological interaction (PPI) implemented in SPM8 (Friston et al., 
1997). For direct comparison, we focused on NVJ-specific PPI from dmPFC to ACC, which 
was significantly sensitive to single-dose oxytocin (Watanabe, Abe, et al., 2014). At a single-
participant level, this PPI analysis used three regressors: one representing fMRI signals of the 
seed region (i.e., dmPFC), one representing a psychological factor (i.e., NVJ and VJ), and a 
PPI factor. At a group level, we evaluated the significance of PPI in a random effects model. 
 
Statistics 
We calculated oxytocin’s effects on the primary and secondary outcomes using generalised 
estimating equations with an unstructured correlation and robust standard error estimates. 
Changes in these outcomes during each six-week administration were treated as the dependent 
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variables. Main effects and interactions for the pharmacologically different conditions 
(oxytocin/placebo) and the order of drug administration (first/second) were estimated with a 
significance level at P < 0.05. We analysed the secondary outcomes and observational items 
that were assessed every two weeks in essentially the same manner with the order of 
assessments as a factor, instead of the drug order. Changes in rsFC and brain activity in 
ACC/dmPFC were evaluated based on ROI analysis (P < 0.05 in paired t-tests) and voxel-
based analysis around the ROIs (PFWE < 0.05 in small volume correction, SVC). The spatial 
specificity of the ROI analysis was also confirmed in a whole-brain analysis with a statistical 
threshold at Puncorrected < 0.001 and voxel-size > 20 (Lieberman and Cunningham, 2009; 
Wandschneider et al., 2014). We performed corrections for multiple comparisons among all 
the 23 outcomes including the primary and secondary outcomes (i.e., all the scores listed in 
Tables 2 and 3) by calculating false discovery rates (FDRs) (Benjamini and Hochberg, 2000). 
The threshold for FDR was set at 0.05. 
 
 
Results 
Between March 2012 and December 2012, 20 high-functioning adult males with ASD were 
enrolled in this trial, and final assessment at 12th-week endpoint was performed between 
August 2012 and April 2013. Two participants discontinued this trial by themselves because of 
feeling deterioration of their psychiatric symptoms: one of them was in oxytocin administration 
period in oxytocin-first group, whereas the other was in placebo period in placebo-first group 
(Fig. 1A, Table 1). In addition, due to anxiety attacks in an MRI scanner, another individual 
could not complete his final fMRI session that was originally planned after six-week placebo 
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administration. Hence, oxytocin’s effects on clinical scores were assessed based on behavioural 
observations of 18 individuals, whereas its neural effects were evaluated based on fMRI data 
of 17 participants. No major adverse effects were observed, but four participants reported acute 
mild nose irritation (two: placebo period, two: oxytocin period), one had diarrhoea during a 
placebo period, and one felt tired during the entire trial. Fifteen of the 20 individuals 
participated in our previous single-dose trial that was conducted more than a year before this 
trial (Watanabe, Abe, et al., 2014). 
 
Clinical effects 
We first found that six-week oxytocin administration could improve autistic symptoms related 
to social reciprocity (ADOS reciprocity: P = 0.034, Cohen’s d = 0.78, a generalised estimating 
equation, PFDR < 0.05; ADOS communication: P = 0.78, Cohen’s d = 0.03; Fig. 2A) with no 
significant main effect of administration order (first/second) or no significant interaction 
between drug type (oxytocin/placebo) and administration order (P > 0.87).  
This effect size for ADOS reciprocity was preserved even when the effect was 
separately calculated within oxytocin-first group (d = 0.86) and placebo-first group (d = 0.71) 
(Fig. 2B). In addition, even focusing on parallel-group comparison in the first half period of 
this crossover trial, this effect of oxytocin on ADOS reciprocity preserved its effect size (d = 
0. 72; Fig. 2C). Moreover, a comparable effect size was also seen in psychotropic-free 
participants after excluding one participant with continual medication of serotonin-
norepinephrine reuptake inhibitors for his recurrent major depression (d = 0.74). Furthermore, 
even when focusing on changes within the oxytocin periods and comparing post-period ADOS 
scores with pre-period scores, we could still observe a significant proportional decrease in 
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ADOS reciprocity score (%change in ADOS reciprocity: P = 0.025, d = 0.58; cf. %change in 
ADOS communication: P = 0.38, d = 0.20). These results show that, in a social reciprocity 
domain, six-week oxytocin administration improved an ASD core symptom.  
In contrast to the ADOS reciprocity score, neither significant main effects nor 
interactions were found in other primary and secondary clinical outcomes including ADOS 
communication score, ADOS repetitive behaviour score, CARS2 total score, SRS, RBS, AQ, 
QOL, CESD, and STAI (P > 0.1; Table 2).  
Amongst the secondary outcomes and observational items recorded every two weeks, 
CGI-EI and pulse rate showed significant interactions between assessment order and type of 
drug (CGI-EI, P = 0.02, PFDR < 0.05; pulse rate, P < 0.001, PFDR < 0.05). CGI-EI was also 
affected by the assessment order (P = 0.02; Table 3). These results might reflect larger effects 
of the assessment order within oxytocin treatment period (CGI-EI and pulse rate, P < 0.01,) 
than within placebo treatment period (CGI-EI, P = 0.19; pulse rate, P = 0.85). 
 
Effects on intrinsic functional connectivity 
This improvement of social reciprocity deficits was accompanied by enhancement of intrinsic 
functional coordination between pre-defined ACC and dmPFC (Fig. 1B). Six-week oxytocin 
intervention significantly increased rsFC between ACC and dmPFC than placebo 
administration (t16 = 3.5, P = 0.00029, d = 1.1 in a paired t-test, PFDR < 0.05; Fig. 2D), 
independently of the administration order (oxytocin-first group, t16 = 3.6, P = 0.002, d = 1.2; 
placebo-first group, t16 = 3.0, P = 0.008, d = 1.0). The spatial specificity of this effect was 
confirmed by a whole-brain analysis (t = 3.6, P uncorrected < 0.001 and voxel-size > 20; Fig. 2E).  
Moreover, this rsFC increase was strongly correlated with the oxytocin-induced 
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decrease in ADOS reciprocity score (rho = –0.60, P = 0.011; Fig. 2F). Such a correlation 
suggests that neurobiological changes in mPFC underlie the mitigation of the social reciprocity 
deficits, and provides further validation to the observed clinical effect of oxytocin.  
 
Behavioural and neural effects during a psychological task 
We then compared effect sizes of this six-week regimen with those of our previous single-dose 
intervention (Watanabe, Abe, et al., 2014).  
First, we confirmed that the current six-week intervention reproduced qualitatively the 
same behavioural and neural effects as those observed in our previous single-dose trial 
(Watanabe, Abe, et al., 2014): although effects on response time for NVJ were moderate (t16 = 
1.9, P = 0.07, d = 0.50; Fig. 3C), oxytocin-induced increases in the number of NVJ and fixation 
time on eye areas were significant (NVJ number, t16 = 2.6, P = 0.019, d = 0.62, Fig 3B; fixation 
time, t16 = 2.3, P = 0.03, d = 0.56, Fig. 3D; both, PFDR < 0.05).  
In addition to these behavioural effects, oxytocin significantly increased originally-
impaired NVJ-specific activity in ACC and dmPFC (ACC, t16 = 4.2, P = 0.00069, d = 0.97; 
dmPFC, t16 = 3.8, P = 0.0014, d = 0.92 in paired t-tests; PFWE < 0.05 in SVC; Fig. 4A), which 
was confirmed by a whole-brain analysis (t > 3.5, Puncorrected < 0.001, voxel size > 20; Fig. 4B). 
Oxytocin also increased the task-related functional connectivity (PPI) from dmPFC to ACC 
(t16 = 3.5, P = 0.0028, d = 0.83 in a paired t-test, PFWE < 0.05 in SVC; Fig. 4C) with a significant 
spatial specificity (t = 3.8, Puncorrected < 0.001, voxel size > 20; Fig. 4D). 
Furthermore, as in the single-dose trial, these neural effects were predictive of the 
oxytocin-induced increase in the number of NVJ (ACC, r = 0.62, P = 0.01; dmPFC, r = 0.69, 
P = 0.002; dmPFC–ACC, r = 0.55, P = 0.02; Fig. 4E). As a whole, these behavioural and neural 
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responses to the six-week oxytocin administration are qualitatively comparable to those to the 
pervious single-dose intervention (Watanabe, Abe, et al., 2014). 
 
Comparison of effect size between single-dose and six-week regimens 
Quantitatively, however, despite its length, the current six-week regimen did not magnify the 
effects of oxytocin seen in the single-dose administration (Fig. 4F). Based on Cohen’s 
classification (Cohen, 1992), almost all the behavioural and neural effects of this six-week 
intervention had the same levels of effect size as those observed in the single-dose trial 
(Watanabe, Abe, et al., 2014): effects on the number of NVJ and response time for NVJ were 
categorized into medium in both regimens (single-dose/six-week: NVJ number, d = 0.55/0.62; 
response time for NVJ, d = 0.63/0.50); neural effects were large in both (single-dose/six-week: 
ACC activity, d = 1.1/0.97; dmPFC activity, d = 1.1/0.92; task-related functional connectivity, 
d = 0.78/0.83). Only eye-gaze effect was weaker in the six-week administration than in the 
single-dose treatment (single-dose/six-week: d = 0.83/0.56, Cohen’s category: large/medium).  
 
Relationship between clinical and task-related effects 
These neural effects measured in the psychological task also provided further validation to 
oxytocin’s clinical effects: the decrease in ADOS reciprocity score was correlated with the 
increase in NVJ-specific activity of ACC and dmPFC (ACC: rho = –0.67, P = 0.0032, Fig. 5A; 
dmPFC: rho = –0.60, P = 0.011, Fig. 5B) and the enhancement of the task-related functional 
connectivity from dmPFC to ACC (rho = –0.61, P = 0.010; Fig. 5C). These associations suggest 
that oxytocin’s clinical effects on ASD social reciprocity deficits may be supported by 
biological modulations in mPFC.  
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Discussion 
Theses findings suggest that the current six-week intranasal administration of oxytocin could 
clinically mitigate an ASD core symptom about social reciprocity with enhancement of brain 
activity and functional coordination in mPFC. Moreover, we showed that the current six-week 
administration also significantly improved behavioural responses and medial prefrontal 
activity during the task, although the continual intervention did not amplify effects seen in the 
single-dose trial. 
 Such reciprocity-specific effects of oxytocin are consistent with previous findings about 
effects of single-dose oxytocin on neurotypical individuals (Shamay-Tsoory et al., 2009; van 
IJzendoorn and Bakermans-Kranenburg, 2012) and ASD individuals (Hollander et al., 2007). 
Although it did not always positively affect neurotypical individuals (Bartz et al., 2011; 
Bethlehem et al., 2014; De Dreu et al., 2010; 2011; Shalvi and De Dreu, 2014; Shamay-Tsoory 
et al., 2009; Stallen et al., 2012), single-dose oxytocin was found to enhance social cognition 
such as reciprocal cooperation and in-group trust, which indicates qualitative robustness of the 
current observations. 
The current observations are based on an exploratory trial; thus, the relatively small 
number of participants is a potential limitation. In addition, although the oxytocin-induced 
changes were statistically significant and the proportional changes seem to be large (Table 2), 
raw figures of such clinical score changes appear to be relatively small. Therefore, it may be 
somewhat difficult to conclude clinically beneficial effects of continual oxytocin regimens 
merely based on the current results. However, despite this small sample size and seemingly 
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small raw values of the effects, all the observed significant effects had an effect size of >0.5, 
and were classified into medium or large effects (Cohen, 1992). In addition, the improvement 
of ADOS reciprocity score was significantly correlated with multiple neural effects of oxytocin 
(Figs. 2F and 5). Moreover, the decrease in ADOS reciprocity score was weakly correlated 
with the improvement of QOL (ADOS reciprocity change v QOL change, r = –0.21). 
Furthermore, the effect size of the oxytocin-induced improvement of QOL score was relatively 
large (d = 0.45; Table 2). Therefore, these relatively large effect sizes and correlations with 
biological changes and other clinical scores are considered to validate the findings about the 
clinical benefits of continual oxytocin administration. Future studies with a larger sample size 
may detect significant improvement of other clinical scores.  
This study used ADOS, a semi-structured, trained clinician administered, and video-
taped assessment, as its primary outcome, because this ASD-specific assessment system is 
considered to be more reproducible than other subjective and self-reporting scoring systems. 
Although effectiveness of this diagnosis-oriented scale as a primary endpoint should be tested 
in more large-scale future trials, the current significant ADOS-based results provide face 
validation to this selection of clinical outcomes. 
The different effects of oxytocin on different clinical scores (Table 2) may suggest some 
properties of clinical scores that could increase detectability of oxytocin’s effects. First, the 
differences between effects on ADOS sub-domains and those on CARS2 Total suggest that 
oxytocin’s behavioural effects may be more detectable in domain-specific core symptoms than 
general scales. In addition, the differences between ADOS, CES-D, and STAI states imply that 
effects on core symptoms may be generally larger than those on comorbid symptoms. 
Moreover, comparisons between ADOS, AQ, SRS, and QOL scales indicate that objective 
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scoring systems (i.e., ADOS and SRS) might have larger detectability than self-reporting 
methods (i.e., QOL and AQ). Although inter-individual difference may deteriorate the 
sensitivity (e.g., one psychologist evaluates ADOS scoring; 15 different parents score SRS and 
RBS), evaluations by trained examiners (i.e., ADOS) may also increase sensitivity to 
oxytocin’s effects. Finally, considering low detectability of unstructured scales such as CARS2, 
CGI, and GAF (Table 3), semi-structured scoring systems (e.g., ADOS) may be another factor 
to enhance the sensitivity.  
 The current results may have a significant influence on future biological studies and 
clinical trials on oxytocin’s effects on ASD. In theory, it is not necessarily the case that 
continual oxytocin administration induces the same effects seen in single-dose trials. In fact, 
recent clinical trials have reported the difficulty in detecting statistically significant effects of 
oxytocin in continual intervention (Anagnostou et al., 2014, Dadds et al., 2014, Guastella et 
al., 2014), which has raised a possibility that continual regimes induce negative feedback or 
down-regulation and indicated the necessity to search for the optimal time interval between 
oxytocin administrations to avoid the activation of such negative feedback systems and the 
decline of oxytocin’s therapeutic effects. In contrast, the current findings appear to suggest that 
such adverse effects of continual intervention are smaller than expected. In addition, the 
similarity of the effect size between the current continual administration and previous single-
dose trial seems to indicate another possibility that oxytocin’s effects on ASD depend on the 
dose not on the length of administration. If the current observations are applicable to the general 
ASD population, future studies would need to search for the optimal dose of oxytocin rather 
than the administration interval. Collectively, therefore, the current findings appear to indicate 
the necessity to re-consider the effects of long-term oxytocin treatment and its underlying 
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neurobiological mechanisms, and may consequently influence the direction of future clinical 
trials and biological studies on oxytocin’s effects on ASD. 
Although future studies with a larger sample size are necessary to confirm the current 
clinical effect, this study suggests that long-term intranasal administration of oxytocin could 
ameliorate clinically relevant, ASD core social symptoms with robust neural effects. 
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Figure legends 
Fig. 1 
 
Experiment design. 
A. Trial profile. The current exploratory randomised controlled trial first assessed 94 
potential individuals, and selected 20 high-functioning adult ASD males (see Methods). 
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After random assignment to oxytocin-first or placebo-first groups, the 20 participants 
started the 12-week trial. In both groups, one participant quitted the trial by himself 
because they felt worsening of their psychiatric symptoms. The asterisk indicates that 
another participant in oxytocin-first group did not complete his fMRI session on 
Assessment Day 3 after six-week placebo inhalation. Therefore, clinical effects were 
assessed based on data from the 18 participants (Table 1), whereas effects related to a 
psychological task were evaluated on data from the 17 individuals. Effects of each 
intervention were defined as differences between before and after the administration.  
B. Evaluation of oxytocin’s neural effects. Oxytocin’s neural effects were evaluated using 
fMRI signal of ACC and dmPFC, because the activity of these regions was originally 
impaired in ASD individuals (Watanabe et al., 2012) and was sensitive to single-dose 
oxytocin (Watanabe, Abe, et al., 2014). First, we measured rsFC between ACC and 
dmPFC. Second, using the same psychological task as one used in our previous studies 
(Watanabe et al., 2012; Watanabe, Abe, et al., 2014; Watanabe, Yahata, et al., 2014), we 
examined effects on task-related activity of these regions and task-related functional 
connectivity (psycho-physiological interaction, PPI) from dmPFC to ACC. In the 
psychological task, participants were asked to make friend/foe judgements based on short 
videos whose verbal and nonverbal information were conflicting to each other.   
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Fig. 2 
 
Effects on clinical scores and rsFC. 
A, B, and C. Effects on clinical score. (A) Unlike ADOS communication score, ADOS social 
reciprocity scores were significantly reduced by six-week oxytocin administration. The 
boxes and bars show box-whisker plots. (B) Although P values did not reach a threshold, 
the large size of the effect (Cohen’s d) on ADOS reciprocity score was essentially preserved 
even when we separately analysed the effects in oxytocin-first and placebo-first groups. 
Error bars: s.e.m. (C) This effect was also seen in parallel-group comparison of drugs’ 
effects on ADOS reciprocity score. Even when focusing on the first half period of the trial, 
we could observe a comparable size of oxytocin’s effect on ADOS reciprocity score. Error 
bars: s.e.m. 
D and E. Effects on rsFC. (D) Oxytocin also significantly increased rsFC between ACC and 
dmPFC. (E) The spatial specificity of the effect on rsFC was confirmed by a whole-brain 
analysis searching for brain regions with a large increase in rsFC with dmPFC. The circle 
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represents approximate location of pre-defined ACC.  
F. Correlation between improvement of clinical scores and enhancement of rsFC. The 
oxytocin-induced change in ADOS reciprocity score was significantly correlated with that 
in rsFC between ACC and dmPFC. Each circle represents each participant.    
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Fig. 3 
 
Behavioural responses during a psychological task. 
A. Task paradigm. In this social cognition task, friend/foe judgements participants made were 
classified into verbal-information-based (VJ) or nonverbal-information-based judgments 
(NVJ). For direct comparison of effect size with our single-dose trial (Watanabe, Abe, et 
al., 2014), we focused on behavioural and brain responses related to NVJ.  
B, C, and D. Behavioural effects. Consistently with effects of single-dose intervention, six-
week oxytocin significantly increased the number of NVJ (B) and fixation time on eye areas 
(D). The effect on response time for NVJ was moderate (C).   
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Fig. 4 
 
Neural responses during psychological tasks 
A and B. Effects on brain activity. (A) Oxytocin significantly increased NVJ-specific activity 
in ACC and dmPFC. (B) The locational specificity of these effects were validated by a whole-
brain analysis. Circles represent approximate location of the pre-defined regions.  
C and D. Effects on task-related functional connectivity. (C) Six-week administration also 
increased task-related functional connectivity (i.e., NVJ-specific PPI) from dmPFC to ACC. 
(D) A whole-brain PPI analysis with dmPFC a seed provided locational validation.  
E. Correlations between oxytocin’s behavioural and neural effects. In the psychological 
task, the behavioural response was correlated with the neural responses. Each circle 
represents each participant.   
F. Comparison of effect size. Despite its continual administration, the effects of the current 
six-week intervention were not larger than those seen in our single-dose trial using the same 
psychological task (Watanabe, Abe, et al., 2014).  
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Fig. 5 
 
Correlations between improvement of clinical score and enhancement of brain activity.  
The improvement of ASD social reciprocity score was not only correlated with an increase in 
ACC-dmPFC rsFC (Fig. 2F), but also accompanied by enhancement of brain activity measured 
during the psychological task, such as the increases in ACC and dmPFC activity (A and B) and 
in task-related functional connectivity (PPI) from dmPFC to ACC (C).   
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Table 1. Demographic Table 
 
  
Oxytocin-initially 
administered group 
Placebo-initially 
administered group   
 (N = 9) (N = 9)  
  Mean (SD) Mean (SD) P value 
Age (range) 35.1(7.6), 24–42 29.3 (5.9), 24–43 0.09 
Height, cm 169.7 (3.8) 167.3 (4.9) 0.27 
Body weight, kg 65.4 (12.6) 66.4 (18.0) 0.89 
SES * 2.7 (0.97) 2.6 (1.0) 0.64 
Parental SES * 2.0 (0.50) 2.4 (0.73) 0.15 
Handedness:  
Right/Mixed/Left 9/0/0 6/1/2  
IQ **    
Full IQ 109.3 (9.1) 101.8 (12.6) 0.17 
Verbal IQ 119.6 (8.1) 104.5 (12.0) 0.01 
Performance IQ 90.9 (12.6) 97.8 (18.9) 0.4 
Autism Diagnostic 
Interview-Revised    
Social 14.0 (6.7) 15.6 (7.2) 0.67 
Communication 13.0 (4.8) 11.3 (3.5) 0.44 
Repetitive 4.1 (2.9) 4.6 (2.1) 0.74 
 
* SES assessed using the Hollingshead. Higher scores indicate lower status. ** The intelligence 
quotients were measured using the Wechsler Adult Intelligence Scale. SES: socio-economic 
status, IQ: intelligence quotient.  
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Table 2. Oxytocin’s effects on main and secondary outcomes measured every six weeks. 
 
 
Note that figures in “Baseline”, “6th week”, and “12th week” columns represent raw values, 
whereas, except fMRI-oriented outcomes, those in OT-/PL-induced changes denote the 
proportion of the change values to the values before the administrations (mean ± std). OT: 
Oxytocin; PL: Placebo; OT-/PL-in: OT-/PL-initially; ADOS: Autism Diagnostic Observation 
Scale; CARS: Childhood Autism Rating Scale; SRS: Social Responsiveness Scale; RBS: 
Repetitive Behaviour Scale; NVJ: Non-verbal information-based judgment; AQ: Autism 
spectrum quotient; QOL: Quality-of-Life questionnaire; STAI: State and Trait Anxiety 
Inventory: CES-D: Centre for Epidemiologic Studies Depression Scale; ACC: Anterior 
cingulate cortex; dmPFC: dorso-medial prefrontal cortex; rsFC: resting-state functional 
connectivity. † indicates PFDR < 0.05.  
Baseline 6th week 12th week
OT-in (n=9) 8.3 (2.1) 7.9 (2.6) 8.7 (2.2)
PL-in (n=9) 7.8 (1.4) 8.6 (2.3) 8.0 (2.1)
OT-in (n=9) 3.8 (1.0) 3.8 (1.2) 4.0 (1.2)
PL-in (n=9) 3.7 (1.9) 3.3 (1.1) 3.7 (1.6)
OT-in (n=9) 0.3 (0.5) 0.3 (0.7) 0.1 (0.3)
PL-in (n=9) 0.4 (0.5) 0.3 (0.5) 0.3 (0.5)
OT-in (n=9) 30.6 (2.8) 31.1 (3.2) 30.7 (2.7)
PL-in (n=9) 31.0 (3.1) 30.9 (3.5) 30.8 (3.4)
OT-in (n=6) 86.7 (20.7) 80.0 (23.3) 77.1 (27.8)
PL-in (n=9) 73.2 (27.4) 71.4 (24.7) 66.2 (21.5)
OT-in (n=6) 14.2 (10.9) 13.7 (12.5) 11.8 (11.2)
PL-in (n=9) 12.2 (9.3) 10.9 (8.4) 7.2 (5.3)
OT-in (n=9) 0.18 (0.09) 0.32 (0.09) 0.18 (0.04)
PL-in (n=8) 0.17 (0.06) 0.16 (0.08) 0.31 (0.06)
OT-in (n=9) 24.7 (4.4) 25.0 (3.5) 23.9 (3.5)
PL-in (n=8) 27.3 (4.9) 26.2 (3.1) 26.5 (3.0)
OT-in (n=9) 2.6 (0.16) 2.2 (0.16) 2.4 (0.26)
PL-in (n=8) 2.4 (0.22) 2.4 (0.22) 2.2 (0.12)
OT-in (n=9) 25.5 (3.1) 29.4 (3.7) 25.8 (2.9)
PL-in (n=8) 27.9 (2.7) 29.9 (3.9) 33.0 (5.6)
OT-in (n=9) 0.10 (0.07) 0.37 (0.08) 0.27 (0.11)
PL-in (n=8) 0.08(0.07) 0.12(0.12) 0.38 (0.09)
OT-in (n=9) 0.17 (0.1) 0.28 (0.09) 0.19 (0.08)
PL-in (n=9) 0.14 (0.07) 0.16 (0.06) 0.27(0.08)
OT-in (n=9) 0.11 (0.12) 0.39 (0.11) 0.24 (0.09)
PL-in (n=8) 0.18 (0.13) 0.09 (0.06) 0.35 (0.15)
OT-in (n=9) 36.8 (6.5) 34.0 (8.3) 33.2 (9.4)
PL-in (n=9) 34.5 (4.7) 34.2 (5.9) 35.3 (5.4)
OT-in (n=9) 3.25 (0.65) 3.28 (0.57) 3.20 (0.65)
PL-in (n=9) 2.68 (0.82) 2.66 (0.96) 2.79 (0.91)
OT-in (n=9) 44.1 (13.4) 46.4 (13.1) 46.3 (13.8)
PL-in (n=9) 50.7 (17.1) 50.6 (17.1) 47.1 (17.8)
OT-in (n=9) 16.1 (11.1) 16.0 (10.8) 14.8 (8.8)
PL-in (n=9) 22.2 (11.9) 20.7 (15.2) 20.2 (16.6) –0.088 (25.3) %
NVJ-specific 
activity: dmPFC 0.0014†
Secondary 
outcomes
0.48
–2.2 (10.0) %
3.5 (7.2) %
0.03† 0.53
0.39 0.32
Fixation time 
for eye area
–4.9 (35.6) %
0.77
Main 
outcomes
–3.1 (19.0) % 0.9 0.045.9 (36.4) %STAI state
0.92
CARS: total
0.78
0.26–13.9 (38.0) %2.5 (34.3) %
0.97
–8.8 (15.2) % 12.2 (24.1) %
9.3 (43.7) % 4.7 (41.6) %
11.8 (6.7) % 4.5 (1.9) %
2.6 (64.8) % –32.5 (61.8) %
0.03†
0.55
RBS
0.1
0.23
SRS
0.450.10.4 (9.8) %
CES-D
QOL
1.9 (9.6) %
–9.9 (6.9) %
0.27 (0.22)
0.10 (0.17) –0.083 (0.12)
P value
0.86 0.14
–0.5 (9.0) %
Six week interval  items
OT-induced 
change
PL-induced 
change Cohen's d
0.03
0.24
–0.033 (0.16)
NVJ number
<0.001†
NVJ response 
time
NVJ-specific 
activity: ACC
AQ score
–4.5 (8.3) % 0.019† 0.62
0.460.09–2.5 (11) %
0.78
0.230.41 (1.6) % –0.10 (2.4) %
–4.9 (17.1) % –5.5 (16.5) %
ADOS: reciprocity
ADOS: 
communication
ADOS: repetitive
rsFC: ACC-
dmPFC 0.15 (0.10) –0.01 (0.13) <0.001† 1.1
Task-related 
func. connectivity 0.002† 0.830.28 (0.44) –0.13 (0.34)
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Table 3. Oxytocin’s effects on outcomes that were measured every two weeks 
 
 
 
CGI: Clinical Global Impressions; GAF: Global Assessment of Functioning; SBP: Systolic blood 
pressure; DBP: diastolic blood pressure; PR: Pulse rate. * The interaction indicates greater time effect 
in oxytocin treatment (P < 0.001) than in placebo treatment (P = 0.19). ** The interaction indicates 
greater time effect in oxytocin treatment (P < 0.001) than in placebo treatment (P = 0.85). † indicates 
PFDR < 0.05. 
Baseline 2nd week 4th week 6th week 8th week 10th week 12th week Time x 
Treatment Treatment Time
OT-in (n=9) NA 10.8 (2.1) 9.9 (2.7) 12.1 (1.8) 11.7 (2.0) 10.3 (2.8) 12.6 (1.3)
PL-in (n=9) NA 10.9 (2.0) 12.2 (1.9) 12.1 (1.8) 12.5 (1.3) 11.2 (2.1) 10.8 (2.1)
OT-in (n=9) 4.2 (1.0) 4.1 (0.9) 4.0 (0.9) 3.9 (0.6) 4.0 (0.9) 4.0 (0.7) 4.0 (0.7)
PL-in (n=9) 4.1 (0.8) 4.0 (0.7) 4.0 (0.7) 4.0 (0.9) 4.0 (0.7) 4.0 (0.9) 4.0 (0.9)
OT-in (n=9) 47.0 (5.4) 48.2 (5.3) 49.4 (5.2) 47.9 (6.2) 50.7 (5.0) 48.7 (6.5) 47.9 (7.2)
PL-in (n=9) 46.2 (5.9) 46.2 (6.7) 46.6 (6.9) 49.9 (5.0) 47.7 (6.8) 50.9 (4.9) 51.1 (4.9)
OT-in (n=9) 115.6 (13.7) 117.3 (12.3) 114.1 (15.3) 117.0 (10.7) 118.7 (13.4) 116.7 (11.2) 114.7 (12.1)
PL-in (n=9) 105.4 (7.7) 117.7 (16.1) 119.3 (10.1) 116.8 (13.8) 110.4 (18.8) 116.4 (12.6) 116.9 (14.4)
OT-in (n=9) 65.6 (13.6) 71.6 (13.7) 73.8 (7.8) 61.6 (6.7) 72.6 (14.0) 70.2 (10.9) 67.4 (7.5)
PL-in (n=9) 58.4 (7.5) 66.2 (14.0) 69.0 (9.2) 66.2 (12.4) 65.1 (11.7) 71.1 (10.5) 66.1 (12.9)
OT-in (n=9) 72.1 (9.5) 79.0 (10.6) 76.1 (8.1) 72.4 (10.8) 75.4 (6.9) 74.8 (12.5) 70.2 (11.7)
PL-in (n=9) 65.2 (7.6) 73.8 (14.7) 73.8 (10.9) 68.6 (9.6) 79.0 (15.7) 78.8 (10.7) 74.7 (9.2)
P value
Secondary 
outcomes
CGI-EI 0.02*† 0.76 0.02
CGI-SI 0.5 0.13
<0.001
Period 1 Period 2
0.52
GAF 0.33 0.56
DBP 0.18 0.36 0.001
PR  < 0.001**† 0.84 0.24
Observation
al items
SBP 0.08 0.09 0.96
